Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Duchenne Muscular Dystrophy Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Duchenne Muscular Dystrophy Therapeutics Overall Market Size
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2021 VS 2028
2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market
3.2 Top Global Duchenne Muscular Dystrophy Therapeutics Companies Ranked by Revenue
3.3 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Duchenne Muscular Dystrophy Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Pain Management Drugs
4.1.3 Corticosteroids
4.1.4 Prednisolone
4.1.5 Prednisone
4.1.6 Deflazacort
4.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Home Care
5.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
6.3.2 US Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.3.3 Canada Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.3.4 Mexico Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
6.4.2 Germany Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.3 France Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.4 U.K. Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.5 Italy Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.6 Russia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.4.8 Benelux Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
6.5.2 China Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5.4 South Korea Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.5.6 India Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
6.6.2 Brazil Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.6.3 Argentina Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028
6.7.2 Turkey Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.7.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
6.7.5 UAE Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028
7 Players Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Corporate Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.1.5 Bristol-Myers Squibb Key News
7.2 FibroGen (US)
7.2.1 FibroGen (US) Corporate Summary
7.2.2 FibroGen (US) Business Overview
7.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.2.5 FibroGen (US) Key News
7.3 Italfarmaco (Italy)
7.3.1 Italfarmaco (Italy) Corporate Summary
7.3.2 Italfarmaco (Italy) Business Overview
7.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.3.5 Italfarmaco (Italy) Key News
7.4 Marathon
7.4.1 Marathon Corporate Summary
7.4.2 Marathon Business Overview
7.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Marathon Key News
7.5 NS Pharma (US)
7.5.1 NS Pharma (US) Corporate Summary
7.5.2 NS Pharma (US) Business Overview
7.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.5.5 NS Pharma (US) Key News
7.6 PTC Therapeutics (US)
7.6.1 PTC Therapeutics (US) Corporate Summary
7.6.2 PTC Therapeutics (US) Business Overview
7.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.6.5 PTC Therapeutics (US) Key News
7.7 Pfizer
7.7.1 Pfizer Corporate Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Pfizer Key News
7.8 ReveraGen BioPharma (US)
7.8.1 ReveraGen BioPharma (US) Corporate Summary
7.8.2 ReveraGen BioPharma (US) Business Overview
7.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.8.5 ReveraGen BioPharma (US) Key News
7.9 Santhera Pharmaceuticals (Switzerland)
7.9.1 Santhera Pharmaceuticals (Switzerland) Corporate Summary
7.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
7.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Santhera Pharmaceuticals (Switzerland) Key News
7.10 Sarepta Therapeutics (US)
7.10.1 Sarepta Therapeutics (US) Corporate Summary
7.10.2 Sarepta Therapeutics (US) Business Overview
7.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Sarepta Therapeutics (US) Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer